Compare AVNS & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNS | ARDX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2014 | 2014 |
| Metric | AVNS | ARDX |
|---|---|---|
| Price | $24.80 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 2.0M | ★ 4.0M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | $2,607,000.00 |
| Revenue This Year | $3.28 | $37.75 |
| Revenue Next Year | $4.23 | $34.24 |
| P/E Ratio | $225.41 | ★ N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $3.54 |
| 52 Week High | $24.81 | $8.40 |
| Indicator | AVNS | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 90.70 | 55.41 |
| Support Level | $12.75 | $5.54 |
| Resistance Level | N/A | $7.43 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.33 | 0.05 |
| Stochastic Oscillator | 64.52 | 52.48 |
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.